Annual report pursuant to Section 13 and 15(d)

Basis of Presentation - Additional Information (Detail)

v3.24.1
Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Feb. 15, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Basis Of Presentation [Line Items]        
Loss from operations   $ 17,937 $ 25,338 $ 16,431
Working capital   5,200 11,200  
Cash and cash equivalents   6,566 4,181  
Net accounts receivable   5,483 5,841  
Net cash and cash equivalents used in operating activities   (14,091) (26,761) (16,710)
Capital Expenditures   1,300    
Net Proceeds from Public Offering   9,553 5,602 14,420
Proceeds from the exercise of warrants   114 $ 1 $ 16,562
Net Proceeds from Public Offering 2023   $ 16,800    
BIOLASE stockholders [Member]        
Basis Of Presentation [Line Items]        
Reverse Stock Split   a reverse stock split of BIOLASE common stock, at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of BIOLASE common stock (the “2023 Reverse Stock Split”). a reverse stock split of BIOLASE common stock, at a ratio ranging from one-for-two (1:2) to one-for-twenty-five (1:25), with the final ratio to be determined by the Board. Immediately after the 2022 Annual Meeting, the Board approved a one-for-twenty-five (1:25) reverse stock split of the outstanding shares of BIOLASE common stock (the “2022 Reverse Stock Split”).  
Subsequent Event [Member]        
Basis Of Presentation [Line Items]        
Net Proceeds from Public Offering $ 7,000      
January 2023 Public Offering [Member]        
Basis Of Presentation [Line Items]        
Net Proceeds from Public Offering   $ 8,500    
May 2023 Public Offering [Member]        
Basis Of Presentation [Line Items]        
Net Proceeds from Public Offering   3,700    
September 2023 Public Offering [Member]        
Basis Of Presentation [Line Items]        
Net Proceeds from Public Offering   3,500    
December 2023 Public Offering [Member]        
Basis Of Presentation [Line Items]        
Net Proceeds from Public Offering   1,100    
Proceeds from the exercise of warrants   $ 800